The Compound Brief

The Compound at 12: The Worked-Example Stack Into Q3, and What's Next for This Briefing

The Compound at 12. The worked-example stack into Q3, and what's next for this briefing.

The Edge Case Issue: Kisspeptin, GHK-Cu, and Three Compounds Worth Watching in H2 2026

The NAD+ Audit: What Three Years of NAD/NMN/NR Hype Actually Did to Bloodwork

The NAD+ audit. Three years of NAD/NMN/NR hype. What the bloodwork actually did.

Everyone Is Wrong About Retatrutide Bloat: It's Not the Reta, It's the Titration

Cognitive Peptides for Founders Who Don't Want a Modafinil Habit: Selank, Semax, and What the Russian Literature Actually Shows

The Growth Stack: CJC-1295 + Ipamorelin vs MK-677 — Pulse vs Plateau